Sara Hurvitz, MD
![](https://education.binayfoundation.org/sites/default/files/styles/faculty_photo/public/faculty/2023-10/headshot%204-2021.jpg?itok=osbbSlJz)
Sara A Hurvitz, MD, is Professor of Medicine at the University of Washington School of Medicine where she serves as Division Head of Hematology/Oncology and Professor of Medicine at the Fred Hutchinson Cancer Center where she serves as Senior Vice President of the Clinical Research Division. Dr. Hurvitz earned her MD from the University of Southern California. She served internship/residency at UCLA, was Chief Resident of internal medicine and completed a hematology-oncology fellowship at UCLA in 2006. Dr. Hurvitz received board-certification in internal medicine, hematology, and medical oncology. Dr. Hurvitz led the breast cancer clinical trials program at UCLA for 17 years and was Medical Director of the Jonsson Comprehensive Cancer Center until 2023 when she accepted a leadership position at UW/FHCC. Dr. Hurvitz has won numerous awards over the past few years, among them the Marni Levine Memorial Breast Cancer Research Award 2008 through 2015 and the European Society of Medical Oncology Breast Cancer Award in 2023. She has an active clinical practice specializing in the treatment of women with breast cancer. She is involved in designing, implementing and leading multiple national and international clinical trials testing new targeted therapies.
Financial relationships
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:Arvinas, Astra Zeneca, Bayer, Celcuity, Cytomx, Daiichi-Sankyo, Dantari, Dignitana, Genentech/Roche, G1-Therapeutics, Gilead, Greenwich Life Sciences Inc, GSK, Immunomedics, Eli Lilly, Macrogenics, Novartis, OBI Pharma, Orinove, Orum, PfizerTopic:Breast Cancer TrialsDate added:10/28/2023Date updated:10/28/2023Relationship end date:07/31/2023
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:Phoenix Molecular Designs, Ltd., Pieris, PUMA, Radius, Samumed, Sanofi, Seattle Genetics/Seagen, ZymeworksTopic:Breast Cancer TrialsDate added:10/28/2023Date updated:10/28/2023Relationship end date:07/31/2023
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:Dantari, LOXOTopic:Breast Cancer TrialsDate added:10/28/2023Date updated:10/28/2023Relationship end date:07/31/2023
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:Onclive, CurioTopic:EducationDate added:10/28/2023Date updated:10/28/2023